RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections

Motsch, J.; Murta de Oliveira, Cláudia; Stus, V.P.; Köksal, İftihar; O. Lyulko, O.; W. Boucher, Helen; S. Kaye, Keith; M. File, Thomas; Brown, Michelle; Khan, Ireen; Du, Jiejun; Joeng, Hee‐Koung; Tipping, Robert; Aggrey, Angela; Young, Katherine; A. Kartsonis, Nicholas; R. Butterton, Joan; Paschke, Amanda

doi:10.1093/cid/ciz530

Public

RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections

Published in Clinical Infectious Diseases • Jun 25, 2019

Authors:

J. Motsch

Cláudia Murta de Oliveira

V.P. Stus

Abstract

BACKGROUND: The β-lactamase inhibitor relebactam can restore imipenem activity against imipenem-nonsusceptible gram-negative pathogens. We evaluated imipenem/relebactam for treating imipenem-nonsusceptible infections. METHODS: Randomized, controlled, double-blind, phase 3 trial. Hospitalized patient...

Subject

Medicine

Imipenem

Colistin

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!